首页> 外国专利> COMBINATION GROWTH FACTOR THERAPY AND CELL THERAPY FOR TREATMENT OF ACUTE AND CHRONIC DISEASES OF THE ORGANS

COMBINATION GROWTH FACTOR THERAPY AND CELL THERAPY FOR TREATMENT OF ACUTE AND CHRONIC DISEASES OF THE ORGANS

机译:联合生长因子疗法和细胞疗法治疗有机器官的急性和慢性疾病

摘要

Ischemia is treated to prevent or manage disease by delivering stem cells derived from cord blood and/or tissue. A patient suffering from disease caused in at least some part by ischemia is selected. At least one dose consisting of an effective amount of stem cells is administrated through intravenous (IV), intra thecal, intra-arterial, via catheter into the organ, via Myostar catheter into the heart, intracoronary, intrapericardial, and/or by direct injection into the organ. Effectiveness of the administration is monitored at selected time periods to determine whether there exists an improved clinical indication. A second dose is administered by a method that is at least invasive as that utilized in the prior dose, and the steps are repeated until the clinical indication shows improvement or until there is contraindication to continued treatment. Diseases include at least one of Ischemia, arteriosclerosis, complications of ischemia, decreased perfusion, aging or diabetes.
机译:通过递送源自脐带血和/或组织的干细胞来治疗缺血,以预防或控制疾病。选择患有至少局部由局部缺血引起的疾病的患者。通过静脉内(IV),鞘内,动脉内,通过导管进入器官,通过Myostar导管进入心脏,冠状动脉内,心包内和/或通过直接注射来施用至少一剂有效量的干细胞进入器官。在选定的时间段监测给药的有效性,以确定是否存在改善的临床适应症。通过与先前剂量中所使用的方法相比具有侵入性的方法来给予第二剂,并且重复这些步骤,直到临床指征显示出改善或直到有继续治疗的禁忌症为止。疾病包括缺血,动脉硬化,缺血并发症,灌注减少,衰老或糖尿病中的至少一种。

著录项

  • 公开/公告号US2018017577A1

    专利类型

  • 公开/公告日2018-01-18

    原文格式PDF

  • 申请/专利权人 WAYNE P. FRANCO;

    申请/专利号US201715637807

  • 发明设计人 WAYNE P. FRANCO;

    申请日2017-06-29

  • 分类号G01N33/68;A61K38/18;

  • 国家 US

  • 入库时间 2022-08-21 13:03:07

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号